H3K27M-EIEs

Preclinical

H3K27M-EIEs is one of 17 therapeutic programs targeting Diffuse Intrinsic Pontine Glioma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diffuse Intrinsic Pontine GliomaNot yet recruiting

Diffuse Intrinsic Pontine GliomaPreclinical

Not yet recruiting

Competition

Competitive Landscape

18 competitors in Diffuse Intrinsic Pontine Glioma

#DrugCompanyPhaseTrials

Verzenio

Farydak

Caprelsa

GGenzyme, a Sanofi Company

Approved

—4

Aldara

BBausch Health Americas, Inc.

Avastin

4 6

Adriamycin

Pfizer

Phase 2

2 7

ONC201

Jazz Pharmaceuticals

Phase 3

3 8

Rituxan

Roche

Phase 1

1 9

Fludara

Sanofi

Phase 1

1 10

Paxalisib

KKazia Therapeutics Limited

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

PreclinicalNot yet recruiting

Diffuse Intrinsic Pontine Glioma

NCT07501156

Clinical

Trials by Indication[1]

Diffuse Intrinsic Pontine Glioma1 trial

H3K27M-specific Engineered Immune Effectors (EIE) Targeting Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma

Not yet recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT07501156·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for H3K27M-EIEs. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for H3K27M-EIEs. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shenzhen Geno-Immune Medical Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SShenzhen Geno-Immune Medical Institute

H3K27M-EIEs

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Diffuse Intrinsic Pontine Glioma1 trial

References

Drug Info

Quick Facts

Related News